Enhertu Approved for Unresectable, Metastatic HER2 & #43; Breast Cancer

MONDAY, Dec. 23, 2019 -- Enhertu (fam-trastuzumab deruxtecan-nxki) has received accelerated approval for treatment of unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the U.S. Food and Drug...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news